InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.490 0.11 (28.95%)+
Announcement
Release
30 Jul 2026 9:47AM
Price at Release
$0.380
Full Release
download
Summary
Island Pharmaceuticals Limited announced a series of strategic and operational updates in its Quarterly Appendix 4C and Activities Report for the period ending June 2026. The company expanded its collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to finalize the study design for its FDA-directed dose optimization study of Galidesivir, which also received FDA Orphan Drug Designation for treating Marburg virus. Additionally, Island secured regulatory approvals to deploy Galidesivir during an Ebola outbreak in Uganda and launched a new program, ISLA-6181, to develop a pre-clinical antiviral molecule. Financially, the company reported a cash balance of $12.87 million and a net cash outflow of $1.53 million. The board approved a salary increase for the CEO and plans to issue options to directors, subject to shareholder approval.
Key Points
  • Island Pharmaceuticals Limited expanded its collaboration with USAMRIID for a dose optimization study.
  • Galidesivir received FDA Orphan Drug Designation for Marburg virus treatment.
  • Company secured government approvals for Galidesivir use during an Ebola outbreak in Uganda.
  • Island Pharmaceuticals launched the new ISLA-6181 program for a pre-clinical antiviral molecule.
  • Company reported cash and cash equivalents of $12.87 million at the end of June 2026.
  • Net cash used in operating activities was $1.53 million for the quarter.
  • CEO and Managing Director's remuneration increased to $400,000 per annum.
  • Plans to issue options to directors pending shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.